Xponance Inc. Has $311,000 Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Xponance Inc. lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 14.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,318 shares of the biopharmaceutical company’s stock after buying an additional 1,326 shares during the quarter. Xponance Inc.’s holdings in TG Therapeutics were worth $311,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Victory Capital Management Inc. grew its holdings in TG Therapeutics by 24.7% in the third quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company’s stock worth $764,000 after purchasing an additional 6,467 shares during the period. Mutual of America Capital Management LLC acquired a new stake in shares of TG Therapeutics in the 3rd quarter valued at about $469,000. Thrivent Financial for Lutherans bought a new stake in TG Therapeutics in the 3rd quarter valued at about $2,450,000. Intech Investment Management LLC acquired a new position in TG Therapeutics during the 3rd quarter worth approximately $1,129,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in TG Therapeutics by 0.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after acquiring an additional 7,939 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Trading Down 1.4 %

Shares of TG Therapeutics stock opened at $40.20 on Friday. The company has a market capitalization of $6.31 billion, a P/E ratio of -401.96 and a beta of 2.30. The stock has a fifty day simple moving average of $34.17 and a 200 day simple moving average of $30.18. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.